PUBLISHER: The Business Research Company | PRODUCT CODE: 1648583
PUBLISHER: The Business Research Company | PRODUCT CODE: 1648583
Clinical chemistry is a field within medical laboratory sciences that emphasizes the qualitative and quantitative analysis of bodily fluids, primarily blood and urine, for diagnosing and monitoring diseases. This discipline involves measuring various biochemical markers or analytes using advanced analytical techniques, delivering essential information that assists healthcare professionals in making informed clinical decisions.
The primary product categories in clinical chemistry comprise analyzers, reagents, and consumables. The term 'analyzer' refers to a laboratory device used to determine the concentration of specific compounds in samples of serum, plasma, urine, and other bodily fluids. These analyzers initiate reactions using reagents, typically applied to the pale-yellow supernatant part (serum) obtained from centrifuged blood or urine samples. Various applications of clinical chemistry include general chemistry tests, liver function tests, kidney function tests, urinalysis, electrolyte panels, lipid profiles, specialty chemical tests, and others. These products find application in hospitals, diagnostic and pathology centers, ambulatory surgery centers, and various other end-user settings.
The clinical chemistry market research report is one of a series of new reports from The Business Research Company that provides clinical chemistry market statistics, including clinical chemistry industry global market size, regional shares, competitors with clinical chemistry market share, detailed clinical chemistry market segments, market trends and opportunities, and any further data you may need to thrive in the clinical chemistry industry. This anomaly detection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The clinical chemistry market size has grown strongly in recent years. It will grow from $15.11 billion in 2024 to $16.11 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to increased diagnostic testing demand, healthcare industry growth, aging population, increased disease diagnosis and management, and research and development.
The clinical chemistry market size is expected to see strong growth in the next few years. It will grow to $22.06 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing demand for precision medicine, growing need for biomarker discovery, increasing demand for personalized healthcare, emerging infectious diseases, and telemedicine and remote monitoring. Major trends in the forecast period include advanced analytical techniques, ai and machine learning integration, technological innovations, laboratory automation, and cutting-edge solutions.
The anticipated increase in the prevalence of chronic diseases is expected to drive the growth of the clinical chemistry market. Chronic diseases, characterized by prolonged duration and the need for continuous medical care, significantly impact global health, with conditions such as diabetes, cancer, and heart disease being leading causes of death and disability. Clinical chemistry plays a vital role in developing and improving techniques for assessing the status and risk of various chronic diseases, including cardiovascular disease, diabetes, and hormone disorders. Additionally, it supports laboratory initiatives related to infectious diseases and flu. According to a September 2023 report from the World Health Organization (WHO), chronic diseases account for 74% of global deaths, totaling 41 million people annually. Hence, the increasing prevalence of chronic diseases is a key driver for the growth of the clinical chemistry market.
The growth of the clinical chemistry market is further fueled by the rising geriatric population. This demographic, consisting of individuals aged 65 or older, plays a crucial role in the demand for clinical chemistry, as it is instrumental in managing age-related diseases such as diabetes, cardiovascular issues, and osteoporosis. According to an October 2022 report from the World Health Organization, the global elderly population is projected to reach 2.1 billion by 2050, with 1 in 6 individuals expected to be 60 or older by 2030. The increasing geriatric population is thus a significant factor contributing to the growth of the clinical chemistry market.
Technological advancements are a significant trend gaining traction in the clinical chemistry market. Leading companies in the clinical chemistry sector are concentrating on integrating new technological solutions to enhance their market position. For example, in May 2022, Mindray, a China-based medical device manufacturer, introduced the BS-600M, a robust clinical chemistry analyzer designed for medium-volume laboratories. This analyzer enhances productivity and reliability in test processing and includes on-board hemolysis for whole blood samples used in HbA1c tests, thus eliminating the need for manual pretreatment. This innovation boosts testing efficiency while minimizing biohazard risks and reducing human errors.
Major companies operating in the clinical chemistry market are intensifying their focus on introducing advanced diagnostic systems, such as the Atellica CI Analyzer, to gain a competitive edge in the market. The Atellica CI Analyzer is a compact testing system developed by Siemens Healthineers, a Germany-based healthcare company. Launched in July 2023, this analyzer is designed to address challenges faced by laboratories in delivering high-quality diagnostics and improving community health. Equipped with features like microvolume technology, an IMT sensor, and independent integration, the Atellica CI Analyzer maximizes test yield, ensures quality results, and maintains high throughput. Offering a comprehensive range of over 200 assays across 20 disease states, it aids in standardizing results and streamlining workflows for entire lab networks.
In May 2024, Bruker, a US-based company that specializes in the design, manufacture, and sale of scientific instruments as well as analytical and diagnostic solutions, acquired ELITechGroup for $954.6 million. This acquisition is intended to strengthen Bruker's position in the molecular diagnostics market, particularly in the infectious disease diagnostics sector. By integrating ELITech's extensive portfolio of molecular diagnostic systems and assays, Bruker seeks to expand its capabilities in infectious disease testing, including viral testing, which is essential for contemporary healthcare requirements. ELITechGroup, based in Italy, develops, manufactures, and markets a wide range of diagnostic products and solutions, encompassing instruments, reagents, and software.
Major companies operating in the clinical chemistry market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., ELITechGroup SAS, Beckman Coulter Inc., Thermo Fisher Scientific Inc., Siemens AG, Ortho Clinical Diagnostics Holdings plc, Diatron Mi Apac Private Limited, Nova Biomedical Corporation, Alfa Wassermann USA Inc., HORIBA Ltd., Mindray Medical International Limited, Randox Laboratories Limited, SYNLAB International GmbH, Agilent Technologies Inc., ARUP Laboratories Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Danaher Corporation, Eurofins Scientific SE, GE Healthcare Technologies Ltd., Laboratory Corporation, Luminex Corporation, PerkinElmer Inc., Quest Diagnostics Incorporated, Sysmex Corporation, Tosoh Corporation, Trinity Biotech plc, Waters Corporation, Werfen S.A.
North America was the largest region in the chemical chemistry market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clinical chemistry market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the clinical chemistry market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The clinical chemistry market includes revenues earned by assays and analyzers. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Clinical Chemistry Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on clinical chemistry market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for clinical chemistry ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The clinical chemistry market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.